Pharma experts identify the true cost of product loss

These events act as a reminder of how far we have come as an Association but they also remind us of why TAPA is so important and the increasing level of risk facing global supply chains. As we know, there is no finishing line in the fight against organised criminals that are targeting high value, theft attractive products. The best we can do is to stay one step ahead. In the last issue of Vigilant, we announced the outcome of our Board election and since then the Board has met and agreed our respective roles for the new three-year term of office. I am extremely proud to be continuing as Chairman of TAPA EMEA and to be working alongside so many supply chain security experts on the Board. The growth of TAPA, the continuous improvements to our Security Standards, the intelligence we provide, and the training we deliver are all driven by the volunteers on our Board and I know this will continue. Despite all having highly responsible and demanding day jobs, every member of the TAPA EMEA.

Spotlight

Ego Pharmaceuticals

Ego exists for people who want healthy skin. Ego is the specialist in skincare, backed by science. We make our products in Australia for the people of the world. We provide consistently high quality products, underpinned by heritage and integrity.

OTHER WHITEPAPERS
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More

Spotlight

Ego Pharmaceuticals

Ego exists for people who want healthy skin. Ego is the specialist in skincare, backed by science. We make our products in Australia for the people of the world. We provide consistently high quality products, underpinned by heritage and integrity.

Events